| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Senior Vice President, Medical | Senior Vice President Medical
1 company
Andreas Maetzel last filed a Form 4 in May 2021, as Senior Vice President, Medical at KALV. Andreas Maetzel's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Andreas Maetzel's trades have earned a strong insider score of 73/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +49.6%.
Andreas Maetzel has 9 Form 4 filings on record from March 2017 to May 2021, all as Senior Vice President, Medical at KalVista Pharmaceuticals (KALV), 2017–2021.
The 21 reported transactions were 8 option or other derivative awards, 7 open-market sales and 6 option exercises.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $2.4M.
The largest open-market sale was 88,030 shares of KALV at an average $25.28 on April 29, 2021, about $2.2M. Twelve months later KALV was down 50%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.